Senseonics (NYSE:SENS) announced today that it received CE mark for the next-generation Eversense E3 CGM system.
Germantown, Maryland-based Senseonics offered its previous-generation continuous glucose monitor (CGM) with a 90-day wear time. Its next-generation Eversense E3 can be used for up to six months (180 days).
Get the full story at our sister site, Drug Delivery Business News.